156 Ramsdell Avenue,
Buffalo, NY 14216.
Phn.: 716-566 7758(R), 716-310 3789(C),
1. August 1999 – June 2005.
PhD from Roswell Park Graduate Division of SUNY, Buffalo, in Molecular and Cellular Biophysics program under Department of Cancer Biology with interaction with Dept of Pharmacology & Therapeutics. Awarded full scholarship and fellowship by Roswell Park Cancer Institute. Title of thesis: NON-INVASIVE IN VIVO ASSESSMENT OF TUMOR HYPOXIA USING FUNCTIONAL MAGNETIC RESONANCE (fMR) IMAGING DURING THERAPY IN HUMAN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) XENOGRAFTS: IMPLICATIONS FOR ASSESSING THERAPEUTIC EFFICACY.
2. October 2002.
Completion of three years study in classical homeopathy with scholarship from the International Academy of Classical Homeopathy, New York. This is a homeopathy course under George Vithoulkas – the winner of 1996 Right Livelihood award (alternate noble prize) for his contribution to the revival of classical homeopathy.
3. December 1997
Masters degree in Psychology (MA) from Annamalai University, India.
4. March 1997
Postgraduate diploma in Guidance and Counseling (PGDGC) from Annamalai University, India
5. Dec 1996
Diploma in Homeopathic Pharmacy (DHPh) from British Institute of Homeopathy, UK.
6. August 1994
Completion of Doctorate of Homeopathic Medicine (HMD) from British institute of Homeopathy, UK.
7. May 1994
Completion of Proficiency certificate in Acupuncture from Chinese Academy of Science.
8. March 1992
Diploma in Acupuncture from Open International University of Complementary Medicine, Sri Lanka.
9. October 1992
Diploma in Homoepathy (DIHom) from British Institute of Homeopathy, UK.
MS in Biophysics from Cancer Research Institute under University of Bombay
BSc in Microbiology from University of Bombay.
1. December 1988
Diploma in Management Studies (DMS) from University of Bombay, India.
2. March 1993
Baccalaureate in law (LLB) from University of Bombay.
3. January 1991
Diploma in Export Import Management from Indian Merchants Chambers, Bombay, India.
CAREER IN HEALTH SCIENCES
1. December 2015 –
Advisor and Steering Committee Member for Wellness and Integrative Medicine Center at Roswell Park Cancer Institute, Buffalo, NY, USA.
2. June 2008 – Sept 2014
Associate Member, Department of Natural Sciences, Roswell Park Graduate Division, State University of New York at Buffalo.
3. June 2009 – till date
Affiliate Member in the Department of Cancer Prevention and Control (2009 – 2016) & in Department of Pharmacology & Therpaeutics (2016 – ) Roswell Park Cancer Institute, Buffalo, NY. Current research involves investigating anticancer properties of natural products such as broccoli, horse radish, wasabi, mustard and selenium in preclinical cancer models including head & neck, lung, colorectal and bladder cancer.
4. September 19, 2005 – May 2009
Postdoctoral training in Translational Pharmacology and Physiology under tutelage of Dr Youcef M Rustum, Distinguished Professor and Chair, Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY. Research involved understanding effect of organoselenium compounds on tumor microenvironment including neoangiogenesis, tumor vessel maturation using various non invasive MR and optical techniques to assess the tumor microenvironment over time and treatment. In vivo xenografts of human lung, colorectal and head/neck cancer models are used along with in vitro tube formation assays for studying angiogenesis. Postdoctoral Fellow from Jan-May 2009 in Department of Cancer Chemoprevention
5. September 2, 2004 till August 31 2004
Research Technologist, Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.
6. April 2002 onwards
a. Homeopathy teacher, tutor, mentor and seminar speaker in North America.
b. Homeopathic Tutor for British Institute of Homeopathy, Canada and USA.
c. Since October 2004, adjunct faculty with Akamai University for homeopathic education.
d. Homeopath practitioner in North America but w.e.f 1st April 2015 do not practice as a homeopath in ON, Canada till my registration is complete with the College of Homeopathy
7. July 1992 till august 1999
Director, coordinator – Centre for Homeopathic Cure, India. Responsibilities included overseeing activities of homeopathic medical doctors at the Centre, teaching intern homeopathic medical doctors, organizing seminars, homeopathic practice, managing finances coordinating different staff and functions.
8. April 1996 till March 1997
Managing Editor – Health Newsletter, India.
Visiting Professor at the Open International University of Complementary Medicine, Sri Lanka teaching homeopathy.
GRANTS AND AWARDS
1. National Institute of Health 2 year R21 award effective May 1st 2009 (CA133682-01A2) ‘Dietary Supplement Selenium and HIF-1 alpha Regulation in Cancer’.
2. American Institute for Cancer Research postdoctoral grant for 2 years effective July 1st. 2006
3. American Association for Cancer Research instituted AACR-AFLAC Scholar-in-Training Award for 2006;
4. International Society for Magnetic Resonance in Medicine Award for annual meeting, 2006;
5. Scholarship from Roswell Park Cancer Institute to attend 7th. International Summer School of Biophysics, Croatia, 2000;
6. Fellowship with scholarship at Roswell Park Cancer Institute & SUNY, Buffalo, NY for PhD studies;
1. #20080019919 – Method for optimizing cancer therapy by monitoring maturation of tumor associated vasculature by selenium;
2. #61/313,004 – Novel method for delivery and use of isothiocyantes and its conjugates against bladder cancer growth and metastasis;
3. #13/609,53 (US), #201180013514.5 (China), #11754150.8 (EP) and #7668/DELNP/2012 – Novel method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer;
4. #62/039,497 & PCT/US15/46000 – Method for prophylaxis and/or treatment of ErbB1 positive cancers;
5. #62/186,439 & PCT/US16/40423 – Diagnostic test for Alzheimer’s disease based on identification of a proteolytic pathway.
OTHER AWARDS AND RECOGNITIONS
1. Doctorate of Science (DSc) – Honoris-Causa by Open International University of Complementary Medicine for services in homeopathy;
2. Recipient of College Merit Scholarship twice at Baccalaureate level;
3. Fellow of the International Laser therapy Association;
4. Fellow of the British Institute of Homeopathy;
5. Fellow member of United Writers’ Association, India;
6. Fellow of the Homeopathic Foundation, Sri Lanka;
7. Fellow of the Acupuncture Foundation of Sri Lanka;
8. HD (Homeopathic Doctor) by HMCC and NUPATH, Canada;
9. SUNY at Buffalo Graduate Student Association Distinguished Service Recognitions as a Finance Commissioner for 2001-2.
1. College of Homeopaths of Ontario since June 2015;
2. Associate member LIGA Medicorum Homeopathica Internationalis since 2016;
3. American Association for Cancer Research (AACR) -1999-2013;
4. International Society For Magnetic Resonance in Medicine (ISMRM) 1999-2013;
5. American Association of Physicists in Medicine (AAPM) 1999-2013;
6. Homeopathic Medical Council of Canada (HMCC) 2002 -2013;
7. National United Professional Association of Trained Homeopaths (NUPATH), Canada 2002-2013;
8. Associate member of the Institute of Company Secretary of India;
9. International German Homoeopathic Society;
10. Commonwealth Institute of Acupuncture & Natural Medicine;
11. Member of the Acupuncture Foundation of SriLanka;
12. Ex-member of Bombay Management Association;
13. Ex-associate member of the International Federation of Practitioners of Natural Therapeutics, UK.
1. Bhattacharya, A., and Y. Zhang. “Role of Homeopathy in Integrative Cancer Care.” Journal of Carcinogenesis & Mutagenesis 6.6 (2015): 7-13.
2. A case of chromosomal translocation causing repeated abortion. Hpathy Ezine, Dec 2014.
3. Homeopathy used as an adjuvant therapy in a metastatic non-small cell lung cancer case. Homeopathy Case Reports, 11.19.2014.
4. Book Chapter: ‘Towards a better understanding of health and disease’ in ‘A compendium of Essays on Alternative Therapy’. ISBN 978-953-307-863-2. Intech-Open Access Publishers, Rijeka, Croatia. 2012.
5. A model of health and disease in homeopathy. The American Homeopath 14, 138-142, 2008.
6. The enigma of coffee restriction in homeopathic treatment. Asian Homeopathic Journal, 6(4), 33-36, 1996.
7. Dietary effect on criminal behaviour. Health Newsletter, 15, 4, 1996.
8. A new model of health and diseases. Health Newsletter, 1996.
9. Alleviating Anxiety neuroses nutritionally. Health Newsletter, 1996.
10. Garlic – the health Panacea. Health Newsletter, 1996.
11. Understanding minerals. Health Newsletter. 1996 & 1997.
1. ‘A compendium of Essays on Alternative Therapy’. ISBN 978-953-307-863-2. Intech-Open Access Publishers, Rijeka, Croatia. 2012.
OTHER SCIENTIFIC PUBLICATIONS
1. Yang L, Bhattacharya A, Zhang Y. A plasma proteolysis pathway comprising blood coagulation proteases. Oncotarget, 2016 Feb 7, doi: 10.18632/oncotarget.7261, 2016.
2. Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ErbB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine, http://dx.doi.org/10.1016/j.ebiom.2015.03.016, 2015.
3. Veeranki O L, Bhattacharya A, Tang L, Marshall J R, Zhang Y. Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer. Curr Pharmacol Rep., DOI 10.1007/s40495-015-0024-z, 2015.
4. Bhattacharya A, Klaene J J, Li Y, Paonessa J, Stablewski A B, Vouros P, Zhang Y. The inverse relationship between bladder and liver in 4-aminobiphenyl-induced DNA damage. Oncotarget, 6(2), 836-845, 2014.
5. Bhattacharya A, Li Y, Shi Y, Zhang Y. Enhanced inhibition of urinary cancer growth and muscle invasion by allyl iothiocyanate and celecoxib in combination. Carcinogenesis, 34(11), 2593-2599, 2013.
6. Veeranki O L, Bhattacharya A, Marshall J R, Zhang Y. Organ-Specific Exposure and Response to Sulforaphane, a Key Chemopreventive Ingredient in Broccoli: Implications for Cancer Prevention. British Journal of Nutrition, 109, 25-32, 2012.
7. Bhattacharya A, Li Y, Geng F, Munday R, Fahey J W, Zhang Y. The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis, 33(2), 394-398, 2012.
8. Azrak R.G, Cao S, Durrani F A, Tóth K, Bhattacharya A, Rustum Y M. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation. Cancer Letters, 311(2), 219-229, 2011, doi:10.1016/j.canlet.2011.07.023.
9. Bhattacharya A. Methylselenocysteine – a Promising Antiangiogenic Agent for Overcoming Drug Delivery Barriers in Solid Malignancies for Therapeutic Synergy with Anticancer Drugs. Expert Opinion on Drug Delivery, 8(6), 749-763, 2011.
10. Bhattacharya A, Turowski S G, San Martin I D, Rajput A, Rustum Y M, Hoffman R M, Seshadri M. Magnetic resonance and fluorescence-protein imaging of anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Research, 31, 387-394, 2011.
11. Bhattacharya A, Turowski S G, San Martin I D, Rajput A, Rustum Y M, Hoffman R M, Seshadri M. Combined magnetic resonance and fluorescence-protein imaging to simultaneously assess the antitumor and anti-antiangiogenesis efficacy of selenium. Proc. Am. Assoc. Cancer Res. (Abstract#4284), 2011.
12. Bhattacharya A, Li Y, Wade K L, Paonessa J D, Fahey J W, Zhang Y. Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion. Carcinogenesis, 31(12), 2105-2110, 2010; doi: 10.1093/carcin/bgq202.
13. Chintala s, Tóth K, Yin M-B, Bhattacharya A, Smith S B, Ola M S, Cao S, Durrani F A, Zinia T R, Dean R, Slocum H K, Rustum Y M. Downregulation of cystine transporter Xc¯ by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy. Chemotherapy, 56(3), 223-233, 2010.
14. Rustum Y M, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison C D, Cao S, Bhattacharya A. Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. Journal on Oncology, Article ID 396286. doi:10.1155/2010/396286.
15. Bhattacharya A, Tang L, Li Y, Geng F, Paonessa J, Chen S C, Wong M, Zhang Y. Inhibition of bladder cancer by allyl isothiocyanate. Carcinogenesis, 31(2), 281-286, 2010; doi: 10.1093/carcin/bgp303.
16. Bhattacharya A, Tang L, Li Y, Geng F, Paonessa J, Chen S C, Wong M, Zhang Y. Bladder cancer inhibition by allyl isothiocyanate. Proc. Am. Assoc. Cancer Res., Frontiers in Cancer prevention Research, 2009.
17. Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky E, Rustum Y M. Inhibition of colon cancer growth by methylselenocysteine – induced angiogenic chemomodulation is influenced by histological characteristics of the tumor. Clinical Colorectal Cancer 8(3), 155-162, 2009. http://cigjournals.metapress.com/content/f31h5xv7268440k9/fulltext.pdf
18. Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum Y M. Hypoxia Specific Drug Tirapazamine Does Not Abrogate Hypoxic Tumor Cells in Combination Therapy with Irinotecan and Methylselenocysteine in Well-Differentiated Human Head and Neck Squamous Cell Carcinoma A253 Xenografts. Neoplasia 10 (8), 857-865, 2008. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481573/pdf/neo1008_0857.pdf
19. Bhattacharya A, Seshadri M, Oven S D, Tóth K, Vaughan M, Rustum Y.M. Tumor vascular maturation and improved drug delivery by organoselenium compound methylselenocysteine. Clinical Cancer Research 14(12), 3926-3932, 2008. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504718/pdf/nihms-59711.pdf
20. Cao S, Durrani FA, Bhattacharya A, Yu Y, Rustum YM. Enhanced irinotecan toxicity in UDPGT deficient rats: Role of UDPGT1A in irinotecan detoxification. Proc. Am. Assoc. Cancer Res., 2008.
21. Bhattacharya A, Tóth K, Cao S, Azrak R. G, Durrani F A, Rustum Y M. 5-Methylselenocysteine (MSC) causes tumor vessel maturation leading to synergistic antitumor effect in human xenografts. Proc. Am. Institute for Cancer Res., 2007.
22. Seshadri M, Bhattacharya A, Tóth K, Rustum Y M. Contrast-enhanced MRI of the vascular response of human tumor xenografts to the chemopreventive agent selenium in vivo: Implications for combination therapy. Proc. Am. Assoc. Cancer Res., 2007.
23. Bhattacharya A, Tóth K, Cao S, Azrak R. G, Durrani F A, Rustum Y M. Se-(Methyl)selenocysteine causes tumor vessel maturation leading to synergistic antitumor effect in human xenografts. The Journal of Nutrition, 137(1S), 278S, 2007.
24. Seshadri M, Mazurchuk R, Spernyak J A, Bhattacharya A, Rustum Y M, Bellnier D A. Activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) against human head and neck carcinoma xenografts. Neoplasia, 8(7), 534-542, 2006. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1601938/pdf/neo0807/0534.pdf
25. Bhattacharya A, Mazurchuk R, Spernyak J. A, Tóth K, Magnano, C.R, Cao S, Azrak R. G, Durrani F A, Rustum Y M. Tumor vessel maturation by 5-Methylselenocysteine (MSC) results in synergistic antitumor effect in human head and neck squamous cell carcinoma (HNSCC) xenografts. Proc. Am. Assoc. Cancer Res., 2006.
26. Bhattacharya A, Mazurchuk R, Spernyak J. A, Cao S, Durrani F A, Rustum Y M. Serial spin echo based BOLD fMR imaging can predict chemotherapy response in head and neck squamous cell carcinoma (HNSCC) xenografts. Proc. International Society of Magnetic Resonance in Medicine, 2006.
27. Seshadri M, Mazurchuk R, Spernyak J. A, Bhattacharya A, Rustum Y M, Bellnier, D.A. Tumor response of human head and neck squamous cell carcinoma (HNSCC) xenografts to the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Proc. Am. Assoc. Cancer Res., 2006
28. Cao S, Bhattacharya A, Durrani F A, Fakih M. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (Review Article). Expert opinion on pharmacotherapy, 7, 687-703, 2006. http://informahealthcare.com/doi/abs/10.1517/14656522.214.171.1247
29. Yin M-B, Li Z-R, Tóth K, Cao S, Durrani F A, Hapke G, Bhattacharya A, Azrak R G, Frank C, Rustum Y M. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase and hypoxia-inducible factor 1 expression, resulting in reduced angiogenesis. Oncogene, 25, 2509-2519, 2006. http://www.nature.com/onc/journal/v25/n17/pdf/1209073a.pdf
30. Bhattacharya A, Tóth K, Mazurchuk R, Spernyak J A, Slocum H K, Pendyala L, Azrak R, Cao S, Durrani F A, Rustum Y M,: Lack of microvessels in well differentiated regions of head and neck squamous cell carcinoma (HNSCC) A253 is associated with fMR imaging detectable hypoxia, limited drug delivery and resistance to irinotecan therapy. Clinical Cancer Res, 10, 8005 – 8017, 2004. http://clincancerres.aacrjournals.org/content/10/23/8005.full.pdf+html
31. Bhattacharya A, Tóth K, Azrak R, Pendyala L, Spernyak J, Cao S, Durrani F A, Mazurchuk R, Slocum H K, Rustum Y M. Resistance to irinotecan is associated with lack of microvessels, hypoxia and limited drug delivery in the well differentiated parts of human head and neck squamous cell carcinoma (HNSCC) A253. Proc. Am. Assoc. Cancer Res. 45, 2004.
32. Cao S, Durrani F A, Moser M T, Bhattacharya A, Foster B A, Rustum Y M. Se-(Methyl)Selenocysteine (MSC) potentiates the antitumor activity of Taxotere against Prostate Cancer inTramp model. Proc. Am. Assoc. Cancer Res, 45, 2004.
33. Bhattacharya A, Azrak R, Toth K, Cao S, Durrani F, Pendyala L, Mazurchuk R, Rustum Y M – Tumor hypoxia and differentiation status are markers associated with response to irinotecan (FU therapy) of xenografts bearing squamous cell carcinoma of the head and neck (SCCHN) tumors. Proc. Am. Assoc. Cancer Res. 44, 2003.
M.S – Thesis Committee and advisor for Steven Oven (‘Tumor vascular maturation by Se-(Methyl)-Selenocysteine in human head and neck squamous cell carcinoma (HNSCC) xenografts’, March 2007).
Summer Students – Mentor for Summer Students Science Program for high school and college students at Roswell Park Cancer Institute, Buffalo, NY.
Homeopathy – Mentor for students and practitioners at various levels of education and training.
SYMPOSIA – ORGANIZER/INVITED SPEAKER/REVIEWER
1/4-1/5/2005 Buffalo, NY
Invited speaker at Selenium Workshop
Title: “Angiogenic activity of selenium: Comparative studies with standard agent”
2/14-2/16/2006 Seattle, Washington
Oral presentation – Oral Scientific Session at 14th. ISMRM Scientific meeting.
Title: “Assessment of spin echo BOLD fMR imaging as a prognostic tool for determining chemotherapeutic efficacy ”
12/30/2007 Toronto, ON
Invited Speaker – Homeopathic Medical Council of Canada
Title: “Cancer and Autoimmune Diseases – A Homeopathic Perspective ”
11/09/2008 Toronto, ON
Invited Keynote Speaker – The National United Professional Association of Trained Homeopaths (NUPATH) Annual Conference
Title: “Homeopathic Detoxification – Freeing the Complex Biological System for Creative Fulfillment.”
11/30/2009 Buffalo, NY
Invited Speaker – Gilda’s Club WNY. Ask the expert lecture
Title: “Cancer and Homeopathy ”
Daemen College, Amherst, NY
Organizer & Part Speaker – co-sponsored by Daemen College and Himalayan Institute, Buffalo.
Title: “Is Homeopathy Effective Against Cancer? The Use of Banerji Protocol in Treatment of Cancer ” Drs Prasanta & Pratip Banerji and Arup Bhattacharya.
10/12- 10/14/2012 Toronto, Canada.
Invited Speaker – Canadian Homeopathic Conference.
Title: “The Magic of Nosodes – Microdoses Mega Results”
10/25/2012 Buffalo, NY
Invited Speaker – Fisher-Price
Title: “Introduction to Homeopathy”
Daemen College, Amherst, NY.
Organizer of a 2 day systems and Symbiosis workshop on
Title: “Harnessing the Power of Bowel Nosodes”. Dr. Russell Malcolm, Dean, Faculty of Homeopathy, UK.
Title: “The Role of Classical homeopathy vs. Homeopathy Protocol Regimen in Modern Day Clinical Practice”.
Buffalo & Erie County Library, Buffalo, NY
Title: “Treatment of advance pathology using homeopathy – underlying principles and concepts”. Dr. Farokh Master.
FSOMA sponsored seminar at East West College, Sarasota, FL
Title: “Harnessing the information patterns in Homeopathy”
Invited Speaker – Canadian Homeopathic Conference. Rogers Prize Excellence in Complementary and Alternative Medicine talk.
Title: “Cancer in Integrative Medicine from a Homeopath’s Perspective”.
05/14-15/2016 BeHealthy Institute, Hamburg, NY.
Title: “Homeopathic Treatment of Mental and Emotional Problems”. Kim Elia
BeHealthy Institute, Hamburg, NY.
Title: “Metabolic and Auto-Immune Disorders”. Dr. Farokh Master
BeHealthy Institute, Hamburg, NY.
Title: “The Elements: Exploring Jan Scholten’s Periodic System”. Sally Williams
04/29/2017 Society for Clinical Research Associate, WNY Chapter Annual Meeting.
Title: “Emerging Alternative Therapies; Treating the Whole Patient”
BeHealthy Institute, Hamburg, NY.
Title: “Homeopathy for Treatment of Cancer”
1. ISMRM – ESMRM 2007 joint annual meeting scientific abstract reviewer;
2. Reviewer for scientific journal such as Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research, Bioorganic & Medicinal Chemistry Letters, Expert Opinion on Emerging Drugs, and, Cancer Epidemiology, Biomarkers & Prevention.
3. Canadian Institute of Health Research – External reviewer since 2008.
4. Featured in ‘Scientist in spotlight’, Fall 2009, American Institute for Cancer Research, AICR ScienceNow, Volume 30, Fall 2009. http://www.aicr.org/site/News2?page=NewsArticle&id=17287&news_iv_ctrl=0&abbr=res_
5. Invited by New York Academy of Sciences to participate in roundtable discussion on critical R&D global challenges for their PepsiCo Company Day on December 10, 2009.